Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HU-436
- Development stage
- Preclinical
- Lead developer
- Yissum
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HU-436 is a synthetic, non-psychoactive analog of cannabidiol (CBD), specifically the methyl ester derivative of cannabidiolic acid (CBDA). It was developed by researchers at the Hebrew University of Jerusalem, including Professor Raphael Mechoulam, and licensed by 180 Life Sciences (formerly CannBioRx) through Yissum. The compound is a lead candidate within the company's Synthetic CBD Analogs (SCA) platform, designed to offer improved stability and therapeutic potency compared to naturally occurring cannabinoids. HU-436 is currently in preclinical development for the treatment of pain and various inflammatory conditions. To address the typical challenges of cannabinoid delivery, the drug is being developed in conjunction with ProNanoLipospheres (PNL) technology to enhance its oral absorption and bioavailability.
- Other names
- cannabidiolic acid methyl esterCBDA-MEHU436HU-436HU 436
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on HU-436.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HU-436.